FDA rejects Burlington biotech ’s schizophrenia drug, sends stock tumbling

Minerva Neurosciences' schizophrenia drug has run into another roadblock on its path to approval.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 27, 2024 Category: Pharmaceuticals Authors: Hannah Green Source Type: news